加载中
Gain Therapeutics, Inc. is a biotechnology firm specializing in the creation of advanced treatments for conditions originating from improperly folded proteins. The company primarily directs its efforts towards rare genetic disorders and neurological ailments. It employs its unique Site-Directed Enzyme Enhancement Therapy (SEE-Tx) platform to pinpoint specific allosteric sites on malformed proteins. Subsequently, Gain Therapeutics identifies proprietary small molecules designed to bind to these locations, thereby restoring correct protein conformation and alleviating the disease. Their current development pipeline includes several structurally targeted allosteric regulator candidates aimed at combating a range of diseases, such as Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1. Established in 2017, the company is headquartered in Bethesda, Maryland.
收盘时
US$1.41
−US$0.16 · -10.19%
盘后
US$1.5245
+US$0.1145 · +8.12%
10月13日 19:59 ET
盘中时间采用ET。市场数据可能有所延迟。
Gain Therapeutics, Inc. is a biotechnology firm specializing in the creation of advanced treatments for conditions originating from improperly folded proteins. The company primarily directs its efforts towards rare genetic disorders and neurological ailments. It employs its unique Site-Directed Enzyme Enhancement Therapy (SEE-Tx) platform to pinpoint specific allosteric sites on malformed proteins. Subsequently, Gain Therapeutics identifies proprietary small molecules designed to bind to these locations, thereby restoring correct protein conformation and alleviating the disease. Their current development pipeline includes several structurally targeted allosteric regulator candidates aimed at combating a range of diseases, such as Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1. Established in 2017, the company is headquartered in Bethesda, Maryland.
日内区间
当前US$1.41
52周区间
当前US$1.41
盘中时间采用ET。市场数据可能有所延迟。
Gain Therapeutics, Inc. is a biotechnology firm specializing in the creation of advanced treatments for conditions originating from improperly folded proteins. The company primarily directs its efforts towards rare genetic disorders and neurological ailments. It employs its unique Site-Directed Enzyme Enhancement Therapy (SEE-Tx) platform to pinpoint specific allosteric sites on malformed proteins. Subsequently, Gain Therapeutics identifies proprietary small molecules designed to bind to these locations, thereby restoring correct protein conformation and alleviating the disease. Their current development pipeline includes several structurally targeted allosteric regulator candidates aimed at combating a range of diseases, such as Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1. Established in 2017, the company is headquartered in Bethesda, Maryland.
日内区间
当前US$1.41
52周区间
当前US$1.41
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | — | — | 5.52万 USD | 14.01万 USD | 16.5万 USD |
| 毛利 | — | — | 5.52万 USD | 14.01万 USD | 16.5万 USD |
| 研究与开发 | 1021.28万 USD | 1079.11万 USD | 1152.06万 USD | 837.73万 USD | 716.42万 USD |
| 销售、一般及管理费用 | 849.79万 USD | 955.95万 USD | 1078.77万 USD | 953.99万 USD | 682.69万 USD |
| 营业费用 | 1871.07万 USD | 2035.06万 USD | 2230.83万 USD | 1791.72万 USD | 1399.12万 USD |
| 利息收入 | 24.44万 USD | 35.71万 USD | 49.42万 USD | 37.54万 USD | 1.25万 USD |
| 折旧和摊销 | 9.4万 USD | 8.41万 USD | 8.36万 USD | 6.42万 USD | 1.55万 USD |
| 营业利润 | −1871.07万 USD | −2035.06万 USD | −2225.31万 USD | −1777.7万 USD | −1382.62万 USD |
| 净利润 | −2016.11万 USD | −2041.12万 USD | −2226.75万 USD | −1759.07万 USD | −1389.06万 USD |
公司数据更新于 2026年10月14日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$5.00
上涨空间 254.61%报告持有此股票敞口的交易所交易基金。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
